Search Results for "Antagon"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Antagon. Results 11 to 15 of 15 total matches.
See also: ganirelix acetate
Drugs for Overactive Bladder
The Medical Letter on Drugs and Therapeutics • Mar 20, 2023 (Issue 1672)
— Anticholinergic drugs
relax the detrusor muscle by antagonizing muscarinic
receptors in the bladder. Six ...
In overactive bladder, involuntary bladder contractions
due to detrusor overactivity result in urinary
urgency, frequency, nocturia, and incontinence.
The prevalence of the disorder increases with age.
Nonpharmacologic treatment, including bladder
training, urge suppression, pelvic floor muscle
exercises, constipation management, modification of
fluid intake, and avoidance of dietary irritants such as
alcohol and caffeine, should be tried first.
Med Lett Drugs Ther. 2023 Mar 20;65(1672):41-5 doi:10.58347/tml.2023.1672a | Show Introduction Hide Introduction
Drugs for Gout
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023 (Issue 1688)
of the toxic metabolite N-acetylp-
benzoquinone imine (NAPQI). Salicylates can
antagonize the uricosuric ...
Drugs for gout are used to reduce the pain and
inflammation of acute flares, decrease the frequency
of exacerbations, and lower serum urate levels to
prevent recurrent flares, development of tophi, and
joint damage.
Med Lett Drugs Ther. 2023 Oct 30;65(1688):169-75 doi:10.58347/tml.2023.1688a | Show Introduction Hide Introduction
Drugs for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021 (Issue 1618)
antagonize
dopamine to some extent and may reduce the efficacy
of dopamine agonists. Concomitant use of any ...
The motor symptoms of Parkinson's disease (PD) are
caused primarily by degeneration of dopaminergic
neurons in the substantia nigra. The nonmotor symptoms
of the disease are thought to be caused by degeneration of
other neurotransmitter systems. No disease-modifying
drugs are available for treatment of PD.
Drugs for Opioid Use Disorder
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
; 11:iii.
39. SD Comer et al. Depot naltrexone: long-lasting antagonism
of the effects of heroin ...
Opioid use disorder is a chronic, relapsing disease with
physical and psychiatric components. It is associated
with economic hardship, social isolation, incarceration,
increased rates of blood-borne infections such as HIV
and viral hepatitis, adverse pregnancy outcomes, and
increased mortality. According to the NIH, there were
80,411 deaths involving an opioid in the US in 2021,
more than in any previous year. Several guidelines on
the management of opioid use disorder are available;
all recommend maintenance pharmacotherapy as the
standard of care.
Med Lett Drugs Ther. 2023 Sep 4;65(1684):137-44 doi:10.58347/tml.2023.1684a | Show Introduction Hide Introduction
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
-methyl-D-aspartate) receptor
antagonist. NMDA receptor antagonism can
be helpful when other opioids ...
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous issue.